Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
|
|
Author: Lucy J. Sannes, PhD, MBA
As our understanding of cancer has progressed, newer therapies, such as various targeted therapies and immunotherapy, have become an important part of today's cancer treatment regimens. This report focuses on pharmacological therapies–in particular, the pipelines of
|
|
|
Executive Summary Chapter 1 INTRODUCTION 1.1. Background 1.2. Scope of the Report Chapter 2 REVIEW OF HEMATOLOGICAL CANCERS (BLOOD CANCERS) 2.1. Leukemia Acute Lymphocytic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL) Acute Myelogenous (Myeloid) Leukemia (AML) Chronic Myelogenous (Myeloid) Leuke
|
Author: Ken Rubenstein, PhD
Only about 20% of compounds that advance to clinical trials reach the market. Given this high rate of attrition and ever-increasing costs, companies need fallback plans as an alternative to canceling projects and writing off significant investments. Planning optimal backup
|
Author: Peter Norman, MBA, PhD FIGURES Figure 1.1. NDA and BLA Approvals, 2000–2011 Figure 1.2. The Druggable Genome: a) Exploited, b) Potential Figure 2.1. Schematic Representation of Chemical Space Figure 2.2. Progression to Candidates from Leads Figure 2.3. Progression to Candidates from Fragment Leads Fi
|
Executive Summary Chapter 1 INTRODUCTION 1.1. Background 1.2. Scope of the Report Chapter 2 REVIEW OF HEMATOLOGICAL CANCERS (BLOOD CANCERS) 2.1. Leukemia Acute Lymphocytic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL) Acute Myelogenous (Myeloid) Leukemia (AML) Chronic Myelogenous (Myeloid) Leuke
|
Author: Peter Norman, MBA, PhD
Comparison of development candidates derived from fragment-based screens has suggested that such an approach can provide compounds with more drug-like properties than those derived from more conventional screening efforts. The development and application of fragment-based
|
Executive Summary Evolution of the Field and Definitions Technological Aspects of HCA HCA Applications Market Dynamics Observations and Trends Chapter 1 Introduction Scope and Format of the Report Chapter 2 Evolution and Nature of HCA HTS Gives Rise to HCS The Rise of HCS Systems: A Prelude to HCA H
|
Author: Ken Rubenstein, PhD
This Insight Pharma Report focuses on the applications, technology and market aspects of high-content analysis (HCA)—a field that originated when automated microscopic imaging technology joined with the high-throughput screening paradigm that signified the birth of “industrialized
|
3SBio 4SC 7TM Pharma A A5 Laboratories Abbott Ablynx Accentia BioPharmaceuticals Actelion Action Pharma Active Biotech ActoGeniX AcurePharma Addex Adeona Pharmaceuticals Affectis Pharmaceuticals Airmid
|
454 Life Sciences A Accelrys Affymetrix Agencourt Bioscience Agencourt Personal Genomics Agilent Ambry Genetics Amersham Biotech Applied Biosystems Avantome B Beckman Coulter BioNanomatrix Biotage C Caliper
|
Author: K. John Morrow, Jr., PhD Executive Summary Chapter 1 INTRODUCTION 1.1. Scientific Background History of MS Physical Principles Analytical Applications 1.2. The Role of Mass Spectrometry in Genomics/ Proteomics/ Metabolomics/ Lipidomics 1.3. Conclusions: A Versatile Analytical Tool Cha
|
Author: Hermann Mucke, PhD Executive Summary Chapter 1 INTRODUCTION 1.1. From Esoteric Basic Science to the Bioengineered Protein Drug Structure as the Key to Protein Form and Function Antibodies: Immune Proteins Naturally Designed For Combinatorial Diversity 1.2. Leaving the Hype Cycle Legacy Behind
|
Molecular Diagnostics Double Digit Growth AnticipatedAuthored by Ken Rubenstein, PhD| Published February 2011Included in this report 125 Pages 11 Charts, Graphs and Figures Over 130 Companies Exclusive content not available in any other research report. Exclusive to Insight
|
Author: Ken Rubenstein, PhD Executive Summary Evolution of NGS technologies State of the art Systems and technologies on the horizon Market dynamics Chapter 1 INTRODUCTION 1.1 Scope and contents of this report Chapter 2 EVOLUTION OF NGS 2.1 Classical sequencing and early applications 2
|
Author: Ken Rubenstein, PhD
This report focuses on current and innovative NGS technologies, services and markets to answer such questions as;
Which early NGS market entrants have been continually improving and updating their original systems?
Who has introduced new scaled-down
|
Author: K. John Morrow, Jr. Ph.D. CHAPTER 1 INTRODUCTION 1.1. Bioprocessing in the 21st Century A Word of Caution State of the Art What Is Bioprocessing? An Industry Committed to Mammalian Cell Expression Systems (Golden 2009, See Appendix) A Changing Landscape The Pipeline Antibodies Rule
|